Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Sep;104(3):e217-e218.
doi: 10.1016/j.athoracsur.2017.03.038.

Initial Experience With Lung Cancer Resection After Treatment With T-Cell Checkpoint Inhibitors

Jamie E Chaft  1 , Matthew D Hellmann  1 , Moises J Velez  2 , William D Travis  2 , Valerie W Rusch  3
Affiliations
Case Reports

Initial Experience With Lung Cancer Resection After Treatment With T-Cell Checkpoint Inhibitors

Jamie E Chaft et al. Ann Thorac Surg. 2017 Sep.

Abstract

T-cell checkpoint inhibitors targeting the programmed death receptor-1 (PD-1) and its ligand (PD-L1) have recently been approved for the treatment of metastatic non-small cell lung cancer (NSCLC), but their safety and efficacy as neoadjuvant therapy are still undefined. Autoimmune toxicities, notably pneumonitis, are a particular concern in the perioperative setting. This series of 5 cases describes for the first time the safety and technical issues relating to pulmonary resection after checkpoint inhibitor therapy.

PubMed Disclaimer

References

    1. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39. - PMC - PubMed
    1. Brahmer J, Reckamp K, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small cell lung cancer. N Engl J Med. 2015;373(2):123–35. - PMC - PubMed
    1. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csöszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33. - PubMed
    1. Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, et al. Pneumonitis in patients treated with Anti-Programmed Death-1/Programmed Death Ligand 1 therapy. J Clin Oncol. 2016 Sep 19;34 pii: JCO682005. - PMC - PubMed
    1. Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–20. - PubMed

Publication types

MeSH terms